Action of antidepressant and other drugs on norepinephrine systems

Brain Norepinephrine: Neurobiology and Therapeutics

Volumn , Issue , 2007, Pages 515-534

  Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42349113446     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544156.018     Document Type: Chapter

References (66)

1. Kuhn, R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry, 115 (1958), 459-464.
2. Sigg, E. B. Pharmacological studies with tofranil. Can. Psychiatr. Assoc. J., 4: Suppl. (1959), 75-85.
3. Sigg, E. B., Gyermek, L. and Hill, R. T. Antagonism to reserpine induced depression by imipramine, related psychoactive drugs, and some autonomic drugs. Psychopharmacologia, 7 (1965), 144-149.
4. Sen, G. and Bose, K. C. Rawolfia serpentina-a new Indian drug for insanity and high blood-pressure. Indian Med. World, 11 (1931), 194-201.
5. Goodwin, F. K. and Bunney, W. E., Jr.Depressions following reserpine: a reevaluation. Semin. Psychiatry, 3 (1971), 435-448.
6. Schildkraut, J. J.Neuropsychopharmacology and the affective disorders. (First of three parts). New Engl. J. Med., 281 (1969), 302-308.
7. Maas, J. W. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch. Gen. Psychiatry, 32 (1975), 1357-1361.
8. Axelrod, J., Whitby, L. F. and Hertting, G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science, 133 (1961), 383-384.
9. Dengler, H. G., Spiegel, H. E. and Titus, Z. O. Effect of drugs on uptake of isotopic norepinephrine by cat tissues. Nature, 191 (1961), 816-817.
10. Alpers, H. S. and Himwich, H. E. An in vitro study of the effects of tricyclic antidepressant drugs on the accumulation of C14-serotonin by rabbit brain. Biol. Psychiatry, 1 (1969), 81-85.
11. Coyle, J. T. and Snyder, S. H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J. Pharmacol. Exp. Ther., 170 (1969), 221-231.
12. Bolden-Watson, C. and Richelson, E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci., 52 (1993), 1023-1029.
13. Horn, A. S., Coyle, J. T. and Snyder, S. H. Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol. Pharmacol., 7 (1971), 66-80.
14. Richelson, E. and Pfenning, M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol., 104 (1984), 277-286.
15. Mitchell, J. R., Arias, L.andOates, J. A.Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA, 202 (1967), 973-976.
16. Janowsky, D. S., el-Yousef, M. K., Davis, J. M. and Fann, W. E. Antagonism of guanethidine by chlorpromazine. Am. J. Psychiatry, 130 (1973), 808-812.
17. Turker, R. K. and Khairallah, P. A. Demethylimipramine (desipramine), an alpha-adrenergic blocking agent. Experientia, 23 (1967), 252.
18. Glassman, A. H. and Bigger, J. T., Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch. Gen. Psychiatry, 38 (1981), 815-820.
19. Prange, A. J., Jr., Wilson, I. C., Lynn, C.W., Alltop, L. B. and Stikeleather, R. A. L-tryptophan in mania.Contribution toa permissivehypothesis of affective disorders. Arch.Gen.Psychiatry, 30 (1974), 56-62.
20. Emrich, H. M., Berger, M., Riemann, D. and von Zerssen, D. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry, 20 (187), 60-63.
21. Vetulani, J., Stawarz, R. J., Dingell, J.V. and Sulser, F. A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMPgenerating system in the rat limbic forebrain.Naunyn-Schmiedeberg'sArch. Pharmacol., 293 (1976), 109-114.
22. Banerjee, S. P., Kung, L. S., Riggi, S. J. and Chanda, S. K. Development of beta-adrenergic receptor subsensitivity by antidepressants. Nature, 268 (1977), 455-456.
23. Ordway, G. A., Gambarana, C. and Frazer, A. Quantitative autoradiography of central beta adrenoceptor subtypes: comparison of the effects of chronic treatment with desipramine or centrally administered I-isoproterenol. J. Pharmacol. Exp. Ther., 247 (1988), 379-389.
24. Ordway, G. A., Gambarana, C., Tejani-Butt, S. M. et al. Preferential reduction of binding of 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J. Pharmacol. Exp. Ther., 257 (1991), 681-690.
25. Brunello, N., Barbaccia, M. L., Chuang, D. M. and Costa, E. Down-regulation of betaadrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons. Neuropharmacology, 21 (1982), 1145-1149.
26. Garcha, G., Smokcum, R.W., Stephenson, J.D. and Weeramanthri, T. B. Effects of some atypical antidepressants on beta-adrenoceptor binding and adenylate cyclase activity in the rat forebrain. Eur. J. Pharmacol., 108 (1985), 1-7.
27. Kopanski, C., Türck, M. and Schultz, J. Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: structure activity study. Neurochem. Int., 5 (1983), 649-659.
28. Sulser, F. Mode of action of antidepressant drugs. J. Clin. Psychiatry, 44 (1983), 14-20.
29. Nalepa, I., Manier, D. H., Gillespie, D.D. et al. Lack of beta adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur. Neuropsychopharmacol., 8 (1998), 227-232.
30. Mishra, R., Janowsky, A. and Sulser, F. Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: subsensitivity without reduction in beta-adrenergic receptor binding. Neuropharmacology, 19 (1980), 983-987.
31. Crews, F. T. and Smith, C. B. Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science, 202 (1978), 322-324.
32. Yoshioka, M., Matsumoto, M., Numazawa, R. et al. Changes in the regulation of 5-hydroxytryptamine release by alpha(2)-adrenoceptors in the rat hippocampus after longterm desipramine treatment. Eur. J. Pharmacol., 294 (1995), 565-570.
33. Peroutka, S. J. and Snyder, S.H. Long-termantidepressant treatment decreases spiroperidollabeled serotonin receptor binding. Science, 210 (1980), 88-90.
34. Andree, T. H., Mikuni, M., Tong, C. Y., Koenig, J. I. and Meltzer, H. Y. Differential effect of subchronic treatmentwith various neuroleptic agents on serotonin 2 receptors in rat cerebral cortex. J. Neurochem., 46 (1986), 191-197.
35. Maj, J., Klimek, V. and Nowak, G. Antidepressant drugs given repeatedly increase binding to α1-adrenoceptors in the rat cortex. Eur. J. Pharmacol., 119 (1985), 113-116.
36. Menkes, D. B. and Aghajanian, G. K. Alpha 1-adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. Eur. J. Pharmacol., 74 (1981), 27-35.
37. Miller, H. L., Delgado, P. L., Salomon, R. M. et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry, 53 (1996), 117-128.
38. Anderson, I. M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord., 58 (2000), 19-36.
39. Thase, M. E., Entsuah, A. R. and Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry, 178 (2001), 234-241.
40. Vestergaard, P., Gram, L. F., Kragh-Sorensen, P. et al. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol. Ser., 10 (1993), 190-198.
41. Arango, V., Underwood, M.D. and Mann, J. J. Alterations in monoamine receptors in the brain of suicide victims. J. Clin. Psychopharmacol., 12 (1992), 8S-12S.
42. De Paermentier, F., Mauger, J. M., Lowther, S. et al. Brain α-adrenoceptors in depressed suicides. Brain Res., 757 (1997), 60-68.
43. Mann, J. J., Stanley, M., McBride, P. A. and McEwen, B. S. Increased serotonin 2 and betaadrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry, 43 (1986), 954-959.
44. Meana, J. J. and Garcia-Sevilla, J. A. Increased α2-adrenoceptor density in the frontal cortex of depressed suicide victims. J. Neural Transm., 70 (1987), 377-381.
45. Ordway, G. A., Widdowson, P. S., Smith, K. S. and Halaris, A. Agonist binding to alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J. Neurochem., 63 (1994), 617-624.
46. Heninger, G. R., Charney, D. S. and Price, L. H. alpha 2-Adrenergic receptor sensitivity in depression. The plasma M. H. P. G, behavioral, and cardiovascular responses to yohimbine. Arch. Gen. Psychiatry, 45 (1988), 718-726.
47. Gann, H., Riemann, D., Stoll, S., Berger, M. andMuller, W. E. Growth hormone response to growth hormone-releasing hormone and clonidine in depression. Biol. Psychiatry, 38 (1995), 325-329.
48. Bertschy, G., Vandel, S., Puech, A. et al. Cardiac beta-adrenergic sensitivity in depression: relationwith endogenous subtype and desipramine response. Neuropsychobiology, 21 (1989), 177-181.
49. Attar-Lévy, D., Martinot, J. L., Blin, J. et al. The cortical serotonin(2) receptors studied with positron-emission tomography and [F-18]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol. Psychiatry, 45 (1999), 180-186.
50. Biver, F., Wikler, D., Lotstra, F. et al. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br. J. Psychiatry, 171 (1997), 444-448.
51. Meltzer, C. C., Price, J. C., Mathis, C. A. et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry, 156 (1999), 1871-1878.
52. Meyer, J. H., Kapur, S., Houle, S. et al. Prefrontal cortex 5-HT2 receptors in depression: an [F-18]setoperone PET imaging study. Am. J. Psychiatry, 156 (1999), 1029-1034.
53. Yatham, L. N., Liddle, P. F., Shiah, I. S. et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch. Gen. Psychiatry, 57 (2000), 850-858.
54. Pacholczyk, T., Blakely, R.D. and Amara, S. G. Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature, 350 (1991), 350-354.
55. Klimek, V., Stockmeier, C., Overholser, J. et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci., 17 (1997), 8451-8458.
56. Ordway, G. A., Stockmeier, C. A., Cason, G.W.andKlimek, V. Pharmacologyanddistribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J. Neurosci., 17 (1997), 1710-1719.
57. Carlier, P. R., Lo, M.M. C., Lo, P. C. K. et al. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopaminereuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg.Med. Chem. Lett., 8 (1998), 487-492.
58. Tatsumi, M., Groshan, K., Blakely, R.D. and Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol., 340 (1997), 249-258.
59. Tatsumi, M., Jansen, K., Blakely, R.D. and Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol., 368 (1999), 277-283.
60. Paczkowski, F. A., Bryan-Lluka, L. J., Porzgen, P., Bruss, M.and Bonisch, H.Comparisonof the pharmacological properties of cloned rat, human, and bovine norepinephrine transporters. J. Pharmacol. Exp. Ther., 290 (1999), 761-767.
61. Harvey, A. T., Rudolph, R. L. and Preskorn, S. H. Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry, 57 (2000), 503-509.
62. Nutt, D. J. Putting the 'A' in atypical: does alpha(2)-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol., 8 (1994), 193-195.
63. Cusack, B., Nelson, A. and Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology, 114 (1994), 559-565.
64. Richelson, E. and Nelson, A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther., 230 (1984), 94-102.
65. Richelson, E. and Nelson, A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol., 103 (1984), 197-204.
66. Richelson, E. and Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci., 68 (2000), 29-39.